Your browser doesn't support javascript.
loading
Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
Uraki, Ryuta; Kiso, Maki; Iwatsuki-Horimoto, Kiyoko; Yamayoshi, Seiya; Ito, Mutsumi; Chiba, Shiho; Sakai-Tagawa, Yuko; Imai, Masaki; Kashima, Yukie; Koga, Michiko; Fuwa, Noriko; Okumura, Nobumasa; Hojo, Masayuki; Iwamoto, Noriko; Kato, Hideaki; Nakajima, Hideaki; Ohmagari, Norio; Yotsuyanagi, Hiroshi; Suzuki, Yutaka; Kawaoka, Yoshihiro.
  • Uraki R; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.
  • Kiso M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Iwatsuki-Horimoto K; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Yamayoshi S; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.
  • Ito M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Chiba S; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Sakai-Tagawa Y; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Imai M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.
  • Kashima Y; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba 277-0882, Japan.
  • Koga M; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Fuwa N; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo 162-8655, Japan.
  • Okumura N; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo 162-8655, Japan.
  • Hojo M; Department of Respiratory Medicine, National Center for Global Health and Medicine Hospital, Tokyo 162-8655, Japan.
  • Iwamoto N; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo 162-8655, Japan.
  • Kato H; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan; Infection Prevention and Control Department, Yokohama City University Hospital, Kanagawa 236-0004, Japan.
  • Nakajima H; Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Kanagawa 236-0004, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo 162-8655, Japan.
  • Yotsuyanagi H; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Suzuki Y; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba 277-0882, Japan.
  • Kawaoka Y; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan; Influenza Research Institute, Department of Pathobiological Science
Cell Rep ; 42(12): 113580, 2023 12 26.
Article en En | MEDLINE | ID: mdl-38103202
ABSTRACT
EG.5.1 is a subvariant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB variant that is rapidly increasing in prevalence worldwide. However, the pathogenicity, transmissibility, and immune evasion properties of isolates of EG.5.1 are largely unknown. Here, we show that there are no obvious differences in growth ability and pathogenicity between EG.5.1 and XBB.1.5 in hamsters. We also demonstrate that, like XBB.1.5, EG.5.1 is transmitted more efficiently between hamsters compared to its predecessor, BA.2. In contrast, unlike XBB.1.5, we detect EG.5.1 in the lungs of four of six exposed hamsters, suggesting that the virus properties of EG.5.1 are different from those of XBB.1.5. Finally, we find that the neutralizing activity of plasma from convalescent individuals against EG.5.1 was slightly, but significantly, lower than that against XBB.1.5 or XBB.1.9.2. Our data suggest that the different virus properties after transmission and the altered antigenicity of EG.5.1 may be driving its increasing prevalence over XBB.1.5 in humans.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article